Treatment of relapsing remitting multiple sclerosis and clinically isolated sydnrome - current recommendations based on new understanding of etiopathogenesis
Abstract
Multiple sclerosis (MS) is a severe neurological disorders affecting almost 20 thousands, mostly young patients in the Czech Republic. There has been clear evidence within the last decades showing that autoimmune inflammation plays a crucial role in the progress of MS.
The problem is that the inflammation is changing its nature and is accompanied by neurodegeneration from the beginning of the disease. Neurodegeneration is later on responsible for disability.
The only possibility how to positively influence the progression of the disease with our current anti-inflammatory drugs is to start treatment early. Treatment must be complex with the aim to influence different pathogenic mechanisms.
Due to the high variability in the progression of MS, careful monitoring of the effectiveness of treatment is an essential condition. The Standars for Diagnostics and Treatment of MS and Neuromyelitis Optica (available at www.czech-neuro.cz, http://www.sopr.cz/standardy/) summarize the most recent treatment recommendations